Format

Send to

Choose Destination
J Control Release. 2014 Sep 10;189:123-132. doi: 10.1016/j.jconrel.2014.06.031. Epub 2014 Jun 28.

Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood-brain barrier using MRI-guided focused ultrasound.

Author information

1
Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231 (USA).
2
Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218 (USA).
3
Department of Biomedical Engineering, University of Virginia, Charlottesville, VA 22908 (USA).
4
Department of Radiology, University of Virginia, Charlottesville, VA 22908 (USA).
5
Department of Internal Medicine, Cardiovascular Division, University of Virginia, Charlottesville, VA 22908 (USA).
6
Department of Neurosurgery, University of Maryland, Baltimore, MD 21201 (USA).
7
Department of Ophthalmology, The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21231 (USA).
#
Contributed equally

Abstract

The blood-brain barrier (BBB) presents a significant obstacle for the treatment of many central nervous system (CNS) disorders, including invasive brain tumors, Alzheimer's, Parkinson's and stroke. Therapeutics must be capable of bypassing the BBB and also penetrate the brain parenchyma to achieve a desired effect within the brain. In this study, we test the unique combination of a non-invasive approach to BBB permeabilization with a therapeutically relevant polymeric nanoparticle platform capable of rapidly penetrating within the brain microenvironment. MR-guided focused ultrasound (FUS) with intravascular microbubbles (MBs) is able to locally and reversibly disrupt the BBB with submillimeter spatial accuracy. Densely poly(ethylene-co-glycol) (PEG) coated, brain-penetrating nanoparticles (BPNs) are long-circulating and diffuse 10-fold slower in normal rat brain tissue compared to diffusion in water. Following intravenous administration of model and biodegradable BPNs in normal healthy rats, we demonstrate safe, pressure-dependent delivery of 60nm BPNs to the brain parenchyma in regions where the BBB is disrupted by FUS and MBs. Delivery of BPNs with MR-guided FUS has the potential to improve efficacy of treatments for many CNS diseases, while reducing systemic side effects by providing sustained, well-dispersed drug delivery into select regions of the brain.

KEYWORDS:

Central nervous system; Focused ultrasound; Nanoparticles

PMID:
24979210
PMCID:
PMC4125545
DOI:
10.1016/j.jconrel.2014.06.031
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center